Table 1 Clinical and laboratory characteristics of the study population

Age (years)

13.75 ± 4.36

12.55 ± 3.54

0.89

 [Female, n (%)]

28(82.4%)

24(70.6%)

0.72

 [Male, n (%)]

6(17.6%)

10 (29.4%)

Classification

-

 [Systemic, n(%)]

2 (6%)

 [Polyarticular, n(%)]

31 (91.2%)

 [Oligoarticular, n(%)]

1 (2.9%)

 [Psoriatic, n(%)]

1 (2.9%)

 [Enthesitis related, n(%)]

0

 [Unspecified, n(%)]

0

Body mass index (kg/m2)

18.56 ± 4.8

17.35 ± 2.09

0.82

Systolic blood pressure (mmHg)

103.87 ± 13.58

93.21 ± 4.18

0.72

Diastolic blood pressure (mmHg)

65.81 ± 7.56

65.06 ± 5.46

0.84

Heart rate (beats/min)

95.9 ± 13.06

84.12 ± 13.24

0.82

Erythrocyte sedimentation rate (mm/hr.)

32.74 ± 11.55

12.68 ± 2.34

0.01*

C-reactive protein (mg/l)

6.72 ± 2.43

3.12 ± 1.94

0.03*

Rheumatoid factor (+ve)

3 (8.8%)

0 (0%)

JADAS-27

23.51 ± 9.53

-

Disease duration (months)

50.24 ± 15.98

-

Medications:

-

 Patients currently treated with Corticosteroid

4 (11.8%)

 Patients previously treated with Corticosteroid

9 (26.5%)

 Patients treated with NSAIDs

26 (76.5%)

 Patients treated with methotrexate

31 (91.2%)

 Patients treated with Biologic (Etanercept)

3 (8.8%)